Milvexian Fails to Reduce CV Events After ACS

Published Date: 30 Aug 2026

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Read Full News

Latest News

DOACs Benefit AF Patients With Intermediate Stroke Risk

Anticoagulation reduced adverse clinical events in patients with atrial fibrillation at intermediate stroke risk, without an apparent increase in major bleeding.

Heart Failure Drug May Not Improve Exercise Fitness in nHCM

A heart failure drug combination may not improve exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy but is associated with favorable cardiac structural remodeling.

Mounjaro FDA-Approved to Reduce Cardiovascular Risk in T2D

Lilly's Mounjaro (tirzepatide) is now approved to reduce cardiovascular risk in adults with type 2 diabetes.

Weight Down, Steps Down: The GLP-1 Catch

Studies suggest that strong recommendations for exercise with GLP-1s are commonly not heeded; possible reasons vary.

Ginseng, the ‘Miracle Root’: How Strong Is the Evidence?

Evidence varies across ginseng uses, with some potential benefits but limited support for treating fatigue, cognitive decline, infections, diabetes, or cardiovascular disease.

Inpatient Weight Loss May Cut HF Rehospitalization Risk

Losing weight during hospitalization for heart failure in patients treated with intravenous loop diuretics is associated with a reduced 30-day risk for rehospitalization.

Todays Updates

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

Anticoagulation reduced adverse clinical events in patients with atrial fibrillation at intermediate stroke risk, without an apparent increase in major bleeding.

A heart failure drug combination may not improve exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy but is associated with favorable cardiac structural remodeling.

Lilly's Mounjaro (tirzepatide) is now approved to reduce cardiovascular risk in adults with type 2 diabetes.

Studies suggest that strong recommendations for exercise with GLP-1s are commonly not heeded; possible reasons vary.

Evidence varies across ginseng uses, with some potential benefits but limited support for treating fatigue, cognitive decline, infections, diabetes, or cardiovascular disease.

Losing weight during hospitalization for heart failure in patients treated with intravenous loop diuretics is associated with a reduced 30-day risk for rehospitalization.

News All Time

Vutrisiran May Stabilize Right Ventricle Function in ATTR-CM

Right ventricular dysfunction is linked to worse outcomes in patients with transthyretin amyloidosis with cardiomyopathy; vutrisiran treatment may help stabilize right ventricular function.

Inhaling Cannabis Tied to Less Cardiac Ectopy in Adults

Adults without a history of cardiac arrhythmias have less cardiac ectopy on days they were randomly assigned to inhale cannabis than on days they abstained.

Mildly Elevated Ketones May Protect Kidneys in T2D

In patients with type 2 diabetes, mildly elevated blood ketone body levels are associated with a lower risk of developing kidney complications, a study finds.

Common ASM Tied to Twofold Thromboembolic Risk With DOACs

Levetiracetam has been linked to an increased thromboembolic risk among adults with epilepsy receiving DOACs, but experts caution that, at this point, the finding is not practice-changing.

An Accordion’s Unlikely Assist in Heart Research

Researchers applied the physics of the instrument to a new device that reproduces the heart’s complex blood flow waveforms.

Mushrooms Gain Ground in Medicine Despite Limited Evidence

Mushroom compounds show potential across cancer, metabolic, and neurologic research, but most evidence remains preclinical and larger clinical trials are still needed.

Doctors Need Friends Outside Medicine, and It’s Not Easy

Doctors may find their closest friends in medicine and have little time for others. But experts say friendships outside the medical bubble matter more than ever.

Cardioprotection Rarely Used in Adults With Blood Cancers

Few adults on anthracycline chemotherapy for hematologic cancers receive strategies to protect their hearts.

Breakthrough Stroke in AF Linked to Drug Interactions

Patients who experience ischemic stroke despite ongoing oral anticoagulation for atrial fibrillation often have identifiable causes such as drug interactions or non-cardioembolic disease.

Medicine on Screen: 10 Films Doctors May Want to Rewatch

From Alzheimer’s to pandemics, these films show how medicine is lived as much as it is practiced.

Sequential or Simultaneous Therapy in Chronic Kidney Disease

Experts debate the pros and cons of stepwise vs simultaneous therapy for chronic kidney disease in an era of multifactorial treatment choices.

Deep Dive: DPP-4 Inhibitors After the ADA Downgrade

ADA now says limit or discontinue gliptins. Cardiologist Benjamin Scirica, MD, on why sitagliptin still looks safest of the four.

New Tool May Identify Adverse Events in Hospitalized Kids

A new trigger tool can help identify adverse events in hospitalized children, showing good reviewer agreement and aiding the systematic detection of patient harm.

Central Obesity Reveals Hidden Risk in Overweight

Adding waist-based central obesity measures to BMI may improve the identification of risk for multimorbidity in adults with BMI-defined overweight.

Canada Joins Global Call for Exercise Physiology for Obesity

A new joint global statement says that exercise physiologists should be part of a multidisciplinary obesity care team for patients taking weight management medications.

Fitness Changes Over Time Linked to Cardiovascular Risk

In adults, changes in cardiorespiratory fitness over time — not just a single measurement — are linked to their risks for cardiovascular disease and death.

Recommended News For You

Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx

Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.

Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer

How breast tissue density affects your risk of breast cancer

Rectal Cancer 'Crisis'; Smells Like Cancer; Flushing Away Clues to Colon Cancer

A small rise in cancer was observed following the 1986 Chernobyl accident.

An Eye Surgeon's Unexpected Discovery of the "Before and After".

Recommended Articles For You

The Surprising Role of Magnesium in Digestion, Sleep and Mental Health  

Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis 

A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures 

Tumor Microenvironment Readiness as a Predictor of Cancer Progression 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

2.

New methods show how fast breast cancers grow and how surgery delays affect cancer staging

3.

Some low-grade prostate cancers carry higher risks than biopsy suggests

4.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

5.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

1.

Unraveling the Mysteries of Hematocrit: How It Impacts Your Health

2.

Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy

3.

Clinical Pharmacology of Erythroid Maturation Pathway Regulators

4.

Precision Medicine for Bone Marrow Microenvironment Remodeling

5.

Everything You Need to Know About HTLV: A Comprehensive Guide 

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

2.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

3.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot